Research Suggests Use of Chemotherapy for Early-Stage Breast Cancer DecliningTarapchak
To estimate the 15-year survival following a diagnosis of stage I breast cancer among women who carry a BRCA1 mutation and to determine predictors of mortality, including the use of chemotherapy. Patients were 379 women with stage I breast cancer for whom a BRCA1 mutation had been identified,...
Before the initiation of chemotherapy, only 66 (44.9%) patients out of 147 patients were indicated for breast-conserving surgery (Fig.1). The most common contraindications for breast-conserving surgery were large tumor size (48.1%), multi-centricity (18.5%), and poor cosmetic outcome (14.8%)....
Cancer stagingis the process of determining how muchcanceris within the body (tumor size) and if it has spread. Forbreast cancer, this might take the form of clinical (pre-surgical) staging or pathologic (surgical) staging. Breast cancer is classified by stages. There are five stages of bre...
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy 来自 EBSCO 喜欢 0 阅读量: 21 作者: J Leichsenring,V Vladimirova,C Solbach,T Karn,B Ataseven,BV Sinn,J Barinoff,V Müller,JU Blohmer,C Schem 展开 ...
The 21-gene recurrence score (RS) assay stratifies early-stage, estrogen receptor-positive breast cancer by recurrence risk. Few studies have examined the ways in which physicians use the RS to recommend adjuvant systemic chemotherapy or patients' experiences with testing and decision making. This ...
The aim of this study was to analyze the correlation between the pathologic complete response (pCR) rate after neoadjuvant chemotherapy and long-term outcome (distant metastases-free survival [DMFS]) in patients with early-stage breast cancer using BluePrint and MammaPrint molecular subtyping versus ...
The main outcomes were associations between RS testing and overall and chemotherapy-specific costs. The primary analysis was restricted to patients aged 66 to 75 years.The primary analysis comprised 30,058 patients. Mean costs 1 year after diagnosis were $35,940 [SD, $28,894] overall, $51,...
Case 1: Approach to Early Stage, HER2+ Breast Cancer Case 4: Chemotherapy or PARP inhibitors for BRCA+ TNBC Case 4: PARP Inhibitors for Treating BRCA+ Triple-Negative Breast Cancer Case 4: OlympiAD Trial for BRCA+ Metastatic TNBC Case 4: BRCA+ Metastatic Breast Cancer Case 3: Treatment Afte...
1. T.T. Alagaratnam, J. Wong Tamoxifen versus chemotherapy as adjuvant treatment in stage III breast cancer Aust NZ J Surg, 56 (1986), pp. 39-41 Google Scholar 2. K. Antman, R.P. Gale Advanced breast cancer: High-dose chemotherapy and bone marrow autotransplant Ann Intern Med, 108...